Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) traded up 6.7% during trading on Wednesday . The stock traded as high as $28.80 and last traded at $28.00, with a volume of 2,387,515 shares trading hands. The stock had previously closed at $26.24.

Several analysts have recently commented on the stock. JMP Securities reaffirmed a “sell” rating and issued a $10.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 3rd. Janney Montgomery Scott reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 7th. Cowen and Company reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 7th. Robert W. Baird reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a report on Sunday, May 8th. Finally, Piper Jaffray Cos. reaffirmed a “sell” rating and issued a $6.00 price objective on shares of Sarepta Therapeutics in a report on Saturday, June 4th. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $25.28.

The stock has a 50 day moving average of $24.26 and a 200-day moving average of $19.15. The stock’s market capitalization is $1.23 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the business earned ($0.87) EPS. On average, equities analysts predict that Sarepta Therapeutics Inc. will post ($5.16) EPS for the current year.

An institutional investor recently raised its position in Sarepta Therapeutics stock. Jennison Associates LLC boosted its stake in shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) by 463.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 838,629 shares of the company’s stock after buying an additional 689,831 shares during the period. Jennison Associates LLC owned about 1.85% of Sarepta Therapeutics worth $32,354,000 at the end of the most recent quarter.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.